CervoMed Inc. (CRVO)
CRVO Stock Price Chart
Explore CervoMed Inc. interactive price chart. Choose custom timeframes to analyze CRVO price movements and trends.
CRVO Company Profile
Discover essential business fundamentals and corporate details for CervoMed Inc. (CRVO) to support your stock research and investment decisions.
Sector
Healthcare
Industry
Biotechnology
IPO Date
23 May 2008
Employees
15.00
Website
https://www.cervomed.comCEO
John J. Alam
Description
CervoMed Inc., a clinical-stage biotechnology company, engages in the development and commercialization of drug treatments for neurodegenerative diseases. It develops neflamapimod, an orally administered small molecule brain penetrant for the treatment of dementia with Lewy bodies (DLB), Alzheimer's diseases, and brain stroke recovery. The company is based in Boston, Massachusetts.
CRVO Financial Timeline
Browse a chronological timeline of CervoMed Inc. corporate events including earnings releases, dividend announcements, and stock splits.
Upcoming earnings on 16 Mar 2026
Upcoming earnings on 11 Nov 2025
EPS estimate is -$0.68.
Earnings released on 8 Aug 2025
EPS came in at -$0.70 falling short of the estimated -$0.57 by -22.81%, while revenue for the quarter reached $1.76M , beating expectations by +22.63%.
Earnings released on 12 May 2025
EPS came in at -$0.56 surpassing the estimated -$0.60 by +6.67%, while revenue for the quarter reached $1.92M , beating expectations by +30.69%.
Earnings released on 17 Mar 2025
EPS came in at -$0.80 falling short of the estimated -$0.67 by -19.40%, while revenue for the quarter reached $2.16M , beating expectations by +40.36%.
Earnings released on 12 Nov 2024
EPS came in at -$0.55 falling short of the estimated -$0.41 by -34.15%, while revenue for the quarter reached $1.94M , beating expectations by +6.65%.
Earnings released on 9 Aug 2024
EPS came in at -$0.27 falling short of the estimated -$0.24 by -12.50%, while revenue for the quarter reached $3.29M , beating expectations by +49.50%.
Earnings released on 14 May 2024
EPS came in at -$0.41 surpassing the estimated -$0.46 by +10.87%, while revenue for the quarter reached $2.35M , beating expectations by +73.87%.
Earnings released on 25 Mar 2024
EPS came in at -$0.38 falling short of the estimated -$0.29 by -31.03%, while revenue for the quarter reached $2.49M , beating expectations by +24.53%.
Earnings released on 13 Nov 2023
EPS came in at -$0.70 surpassing the estimated -$0.95 by +26.32%, while revenue for the quarter reached $1.53M .
Stock split effective on 17 Aug 2023
Shares were split 2 : 3 , changing the number of shares outstanding and the price per share accordingly.
Earnings released on 8 Aug 2023
EPS came in at -$1.04 surpassing the estimated -$2.90 by +64.08%.
Earnings released on 15 May 2023
EPS came in at -$3.01 falling short of the estimated -$2.87 by -5.04%, while revenue for the quarter reached $1.41M .
Earnings released on 31 Dec 2022
EPS came in at -$3.00 surpassing the estimated -$3.30 by +9.15%.
Earnings released on 29 Sept 2022
EPS came in at -$2.06 surpassing the estimated -$3.09 by +33.38%.
Earnings released on 29 Jun 2022
EPS came in at -$3.08 .
Stock split effective on 19 Apr 2022
Shares were split 1 : 50 , changing the number of shares outstanding and the price per share accordingly.
Earnings released on 30 Mar 2022
EPS came in at -$3.33 falling short of the estimated -$3.06 by -8.86%.
Earnings released on 30 Dec 2021
EPS came in at -$2.56 .
Earnings released on 29 Sept 2021
EPS came in at -$8.98 .
Earnings released on 30 Jun 2021
EPS came in at -$2.78 .
Earnings released on 31 Mar 2021
EPS came in at -$4.22 .
Earnings released on 31 Dec 2020
EPS came in at -$4.94 .
Earnings released on 30 Sept 2020
EPS came in at -$5.20 .
CRVO Stock Performance
Access detailed CRVO performance analysis with candlestick charts, real‑time intraday data and historical financial metrics for comprehensive insights.
Explore Related Stocks
Compare companies within the same sector by viewing performance, key financials, and market trends. Select a symbol to access the full profile.